Silo Pharma, Inc. (SILO)
1.34
+0.05
(+3.88%)
USD |
NASDAQ |
Nov 06, 10:36
Silo Pharma Enterprise Value : -3.977M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | -3.977M |
| November 04, 2026 | -3.932M |
| November 03, 2026 | -3.988M |
| November 02, 2026 | -4.067M |
| October 30, 2026 | -4.044M |
| October 29, 2026 | -4.022M |
| October 28, 2026 | -3.920M |
| October 27, 2026 | -3.977M |
| October 26, 2026 | -4.124M |
| October 23, 2026 | -4.101M |
| October 22, 2026 | -4.101M |
| October 21, 2026 | -4.078M |
| October 20, 2026 | -4.078M |
| October 19, 2026 | -4.157M |
| October 16, 2026 | -4.101M |
| October 15, 2026 | -4.078M |
| October 14, 2026 | -4.078M |
| October 13, 2026 | -4.056M |
| October 12, 2026 | -3.751M |
| October 09, 2026 | -3.774M |
| October 08, 2026 | -3.796M |
| October 07, 2026 | -3.808M |
| October 06, 2026 | -3.796M |
| October 05, 2026 | -3.751M |
| October 02, 2026 | -3.787M |
| Date | Value |
|---|---|
| October 01, 2026 | -3.740M |
| September 30, 2026 | -3.728M |
| September 29, 2026 | -3.616M |
| September 28, 2026 | -3.570M |
| September 25, 2026 | -3.458M |
| September 24, 2026 | -3.458M |
| September 23, 2026 | -3.435M |
| September 22, 2026 | -3.492M |
| September 21, 2026 | -3.463M |
| September 18, 2026 | -3.356M |
| September 17, 2026 | -3.492M |
| September 16, 2026 | -3.446M |
| September 15, 2026 | -3.243M |
| September 14, 2026 | -3.096M |
| September 11, 2026 | -3.063M |
| September 10, 2026 | -3.058M |
| September 09, 2026 | -3.006M |
| September 08, 2026 | -2.860M |
| September 04, 2026 | -2.724M |
| September 03, 2026 | -2.668M |
| September 02, 2026 | -2.611M |
| September 01, 2026 | -2.679M |
| August 31, 2026 | -2.634M |
| August 28, 2026 | -2.566M |
| August 27, 2026 | -2.566M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.737B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Anika Therapeutics, Inc. | 245.53M |
| Savara, Inc. | 757.02M |
| Vericel Corp. | 2.582B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.8328M |
| Total Expenses (Quarterly) | 0.8328M |
| EPS Diluted (Quarterly) | -0.7581 |
| Earnings Yield | -398.4% |
| Normalized Earnings Yield | -390.04 |